UY39979A - Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas - Google Patents

Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas

Info

Publication number
UY39979A
UY39979A UY0001039979A UY39979A UY39979A UY 39979 A UY39979 A UY 39979A UY 0001039979 A UY0001039979 A UY 0001039979A UY 39979 A UY39979 A UY 39979A UY 39979 A UY39979 A UY 39979A
Authority
UY
Uruguay
Prior art keywords
pyrrolo
triazines
preparation
treatment
triazine compounds
Prior art date
Application number
UY0001039979A
Other languages
English (en)
Spanish (es)
Inventor
Gopi Kumar Mittapalli
Kc Sunil Kumar
Chi Ching Mak
Brian Joseph Hofilena
Joseph Timothy Marakovits
Lewis Daniel Turner
Brian Walter Eastman
Ramkrishna Reddy Vakiti
Original Assignee
Biosplice Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosplice Therapeutics Inc filed Critical Biosplice Therapeutics Inc
Publication of UY39979A publication Critical patent/UY39979A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UY0001039979A 2021-10-12 2022-10-12 Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas UY39979A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163254733P 2021-10-12 2021-10-12
US202263347757P 2022-06-01 2022-06-01

Publications (1)

Publication Number Publication Date
UY39979A true UY39979A (es) 2023-04-14

Family

ID=84330173

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039979A UY39979A (es) 2021-10-12 2022-10-12 Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas

Country Status (11)

Country Link
US (2) US12134625B2 (enExample)
EP (1) EP4415816A1 (enExample)
JP (1) JP2024539620A (enExample)
KR (1) KR20240089275A (enExample)
AU (1) AU2022367222A1 (enExample)
CA (1) CA3234831A1 (enExample)
IL (1) IL312157A (enExample)
MX (1) MX2024004552A (enExample)
TW (1) TW202322800A (enExample)
UY (1) UY39979A (enExample)
WO (1) WO2023064366A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119013030A (zh) * 2022-01-25 2024-11-22 金耐特生物制药公司 Cdk4/6激酶的抑制剂
US20240199649A1 (en) * 2022-11-03 2024-06-20 Biosplice Therapeutics, Inc. 4-aminopyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof
WO2024211797A1 (en) * 2023-04-07 2024-10-10 Biosplice Therapeutics, Inc. Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof
CN119019402A (zh) * 2023-05-24 2024-11-26 中国科学院上海有机化学研究所 作为lrrk2激酶抑制剂的多环化合物及其制备方法和用途
WO2025024707A1 (en) * 2023-07-26 2025-01-30 Kinnate Biopharma Inc. Inhibitors of cdk2/4/6 kinase
WO2025137469A1 (en) * 2023-12-22 2025-06-26 Biosplice Therapeutics, Inc. 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164559A (en) 1977-09-21 1979-08-14 Cornell Research Foundation, Inc. Collagen drug delivery device
US4474752A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US6440102B1 (en) 1998-07-23 2002-08-27 Durect Corporation Fluid transfer and diagnostic system for treating the inner ear
DE19853299C2 (de) 1998-11-19 2003-04-03 Thomas Lenarz Katheter zur Applikation von Medikamenten in Flüssigkeitsräumen des menschlichen Innenohrs
US6120484A (en) 1999-02-17 2000-09-19 Silverstein; Herbert Otological implant for delivery of medicament and method of using same
US6967023B1 (en) 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
US6648873B2 (en) 2001-09-21 2003-11-18 Durect Corp. Aural catheter system including anchor balloon and balloon inflation device
PT1730146E (pt) 2004-03-30 2011-07-11 Vertex Pharma Azaindoles úteis como inibidores de jak e outras proteínas quinases
CA2594963A1 (en) 2005-01-24 2006-07-27 Neurosystec Corporation Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues
JP2011526931A (ja) 2008-07-03 2011-10-20 エグゼリクシス， インコーポレイテッド Ｃｄｋモジュレーター
WO2011018894A1 (en) 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
EP2935248B1 (en) 2012-12-21 2018-02-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2016010886A1 (en) 2014-07-14 2016-01-21 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
AU2016315881B2 (en) 2015-09-03 2019-09-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK1A and uses thereof
FR3041640B1 (fr) 2015-09-30 2019-05-17 Les Laboratoires Servier NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
JP2020536920A (ja) * 2017-10-10 2020-12-17 サイロス ファーマシューティカルズ， インコーポレイテッド ピロロトリアジン化合物およびｔａｍキナーゼを阻害する方法
US20200039989A1 (en) 2018-03-01 2020-02-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk/clk and uses thereof
EP3759072A4 (en) 2018-03-01 2021-11-03 The Trustees of Columbia University in the City of New York COMPOUNDS, COMPOSITIONS AND METHODS FOR RELATING TOXIC STRESS FROM ENDOPLASMIC RETICULUM
WO2020006115A1 (en) 2018-06-26 2020-01-02 Betty Tam Methods of treating cancer using a clk inhibitor
CN112867493A (zh) 2018-10-16 2021-05-28 达纳-法伯癌症研究所有限公司 野生型和突变型lrrk2的氮杂吲哚抑制剂
US20230000842A1 (en) 2019-01-17 2023-01-05 Samumed, Llc Methods of treating cartilage disorders through inhibition of clk and dyrk
WO2021257863A1 (en) * 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
EP4182320A1 (en) 2020-07-20 2023-05-24 Nido Biosciences, Inc. Indole compounds as androgen receptor modulators
US20230192686A1 (en) 2021-10-12 2023-06-22 Biosplice Therapeutics, Inc. 1h-pyrrolo[2,3-b]pyridines and preparation and uses thereof
TW202330533A (zh) 2021-10-12 2023-08-01 美商生物銜接醫療公司 7h-吡咯并[2,3-d]嘧啶及其製備及用途
CN119604506A (zh) 2022-06-23 2025-03-11 拜斯丽治疗有限公司 4-烷氧基吡咯并[2,1-f][1,2,4]三嗪以及其制备和用途

Also Published As

Publication number Publication date
US20230312605A1 (en) 2023-10-05
IL312157A (en) 2024-06-01
WO2023064366A1 (en) 2023-04-20
EP4415816A1 (en) 2024-08-21
CA3234831A1 (en) 2023-04-20
MX2024004552A (es) 2024-06-04
AU2022367222A1 (en) 2024-05-02
US12134625B2 (en) 2024-11-05
TW202322800A (zh) 2023-06-16
US20250171466A1 (en) 2025-05-29
JP2024539620A (ja) 2024-10-29
KR20240089275A (ko) 2024-06-20

Similar Documents

Publication Publication Date Title
UY39979A (es) Pirrolo[2,1-f][1,2,4]triazinas y preparación y usos de las mismas
UY39978A (es) 7h-pirrolo[2,3-d]pirimidinas y preparación y usos de las mismas
CO2022014073A2 (es) Compuestos antivirales y métodos para la administración de los mismos
BR0307819A (pt) Derivados de pirazol tricìclicos, processo para preparação dos mesmos como agentes antitumorais
CO2022008243A2 (es) Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos
BR112017018022A2 (pt) "compostos antivirais, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
MX2024015663A (es) 4-alcoxipirrolo[2,1-f][1,2,4]triazinas y preparación y uso de las mismas
BR112016003348A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade efetiva de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
SA98190487B1 (ar) مركبات ثلاثي 3.2.1- ازولو ]4،5- D [ بيريميدين1,2,3-triazolo[4,5-D] pyrimidines حديثه واستخداماتها كعقاقير وطرق لتحضيرها
AR048912A1 (es) Inmunoglobulinas anti-nogo
BR9812048A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos de tratar uma doença mediada por uma cinase, de tratar a rejeição no transplante de órgão, e de tratar a alopecia induzida pela quimioterapia
CO2023009368A2 (es) Cocristal de un inhibidor de cdk
BR112021000796A2 (pt) Processo para a fabricação de (6ar,10ar)-7-propil-6,6a,7,8,9,10,10a,11-octa-hidro-[1,3]dioxolo[4',5':5,6]benzo[1,2-g]quinolina e (4ar,10ar)-1-propil-1,2,3,4,4a,5,10,10a-octa-hidro-benzo[g]quinolina-6,7-diol
CO6300934A2 (es) Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparacion de las mismas
BR0213539A (pt) Compostos, processo para a preparação de compostos, composições farmacêuticas que compreendem um composto método para o tratamento e/ou profilaxia de enfermidades que estão associadas com dpp iv e utilização desses compostos
HN2003000348A (es) Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas.
CO6321264A2 (es) Derivados de 1-heterociclilo-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona y su uso como moduladores de la pde9a
BRPI0507041A (pt) composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
MX2025005198A (es) 4-aminopirrolo[2,1-f][1,2,4]triazinas y preparacion y usos de estas
EA202092002A1 (ru) 5-гетероарилзамещенные индазол-3-карбоксамиды и их получение и применение
BR112021020297A2 (pt) Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune
BR112022010181A2 (pt) Composto tri-heterocíclico como inibidor de jak e uso do mesmo
CO2022011183A2 (es) Conjugados de proteínas-compuestos antivirales
BRPI0508428A (pt) fosfonato nucleosìdeos utilizáveis como ingredientes ativos em composições farmacêuticas para o tratamento de infecções virais e intermediários para sua produção